



Catalog#	Description	Size
3465-024-K	Cultrex <sup>®</sup> 24 well Migration Cell Assay	96 samples
3465-096-K	Cultrex <sup>®</sup> 96 well Migration Cell Assay	96 samples
3456-096-K	Cultrex <sup>®</sup> Laminin I Cell Invasion Assay	96 samples
3457-096-K	Cultrex <sup>®</sup> Collagen I Cell Invasion Assay	96 samples
3458-096-K	Cultrex <sup>®</sup> Collagen IV Cell Invasion Assay	96 samples
3490-096-K	CultreCoat <sup>®</sup> BME 96 Well Cell Adhesion Assay	96 samples
3496-096-K	CultreCoat <sup>®</sup> 96 Well Adhesion Protein Array	96 samples
3450-048-SK	Cultrex <sup>®</sup> Directed In Vivo Angiogenesis Assay (DIVAA <sup>™</sup> ) Starter	48 samples
3450-048-K	Cultrex <sup>®</sup> DIVAA <sup>™</sup> Kit	48 samples
3450-048-IK	Cultrex <sup>®</sup> DIVAA <sup>™</sup> Inhibition Kit	48 samples

#### Accessories:

Catalog#	Description	Size
3400-010-02	Cultrex <sup>®</sup> Mouse Laminin I, PathClear <sup>®</sup>	1 ml
3400-010-01	Cultrex <sup>®</sup> Mouse Laminin I	1 mg
3440-100-01	Cultrex <sup>®</sup> Rat Collagen I	100 mg
3410-010-01	Cultrex <sup>®</sup> Mouse Collagen IV	1 mg
3420-001-01	Cultrex <sup>®</sup> Human Fibronectin, PathClear <sup>®</sup>	1 mg
3416-001-01	Cultrex <sup>®</sup> Bovine Fibronectin, NZHD*	1 mg
3421-001-01	Cultrex <sup>®</sup> Human Vitronectin, PathClear <sup>®</sup>	50 µg
3417-001-01	Cultrex <sup>®</sup> Bovine Vitronectin, NZHD	50 µg
3438-100-01	Cultrex <sup>®</sup> Poly-L-Lysine	100 ml
3439-100-01	Cultrex <sup>®</sup> Ploy-D-Lysine	100 ml
3445-048-01	Cultrex <sup>®</sup> 3-D Culture Matrix <sup>™</sup> BME	15 ml
3446-005-01	Cultrex <sup>®</sup> 3-D Culture Matrix <sup>™</sup> Laminin I	5 ml
3447-020-01	Cultrex <sup>®</sup> 3-D Culture Matrix <sup>™</sup> Collagen I	100 mg
3430-005-01	Cultrex <sup>®</sup> BME with Phenol Red	5 ml
3432-005-01	Cultrex <sup>®</sup> BME without Phenol Red	5 ml
3431-005-01	Cultrex <sup>®</sup> BME with Phenol Red; Reduced Growth Factor	5 ml
3433-005-01	Cultrex <sup>®</sup> BME; no Phenol Red; Reduced Growth Factor	5 ml
3415-001-02	Cultrex <sup>®</sup> Human BME, PathClear <sup>®</sup>	1 ml
3430-005-02	Cultrex <sup>®</sup> BME with Phenol Red PathClear <sup>®</sup>	5 ml
3431-005-02	Cultrex <sup>®</sup> BME with Phenol Red, Growth Factor Reduced PathClear <sup>®</sup>	5 ml
3433-005-02	Cultrex <sup>®</sup> BME; no Phenol Red; Reduced Growth Factor PathClear <sup>®</sup>	5 ml
3437-100-K	Cultrex <sup>®</sup> Cell Staining Kit	100 ml
3450-048-05	CellSpense <sup>™</sup>	15 ml

\*New Zealand Herd Derived

#### References:

- Albini, A., Y. Iwamoto, H. Kleinman, G. Martin, S. Aaronson, J. Kozlowski, and R. McEwan. 1987. A rapid *in vitro* assay for quantitating the invasive potential of tumor cells. *Cancer Res.* **47**:3239-3245.
- Fridman, R., G. Giaccone, T. Kanemoto, G. Martin, A. Gazdar, and J. Mulshine. 1990. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. *Proc. Natl. Acad. Sci. USA* **87**:6698-6702.
- Fridman, R., M. Kibbey, L. Royce, M. Zain, T. Sweeney, D. Jicha, J. Yannelli, G. Martin, and H. Kleinman. 1991. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. *J. Natl. Cancer Inst.* **83**:769-774.
- Fridman, R., T. Sweeney, M. Zain, G. Martin, and H. Kleinman. 1992. Malignant transformation of NIH-3T3 cells after subcutaneous co-injection with a reconstituted basement membrane (matrigel). *Int. J. Cancer* **51**:740-744.
- Kubota, Y., H. Kleinman, G. Martin, and T. Lawley. 1988. Role of laminin and basement membrane proteins in the morphological differentiation of human endothelial cells in capillary-like structures. *J. Cell Biol.* **107**:1589-1598.
- Ponce, M., M. Nomizu, M. Delgado, Y. Kuratomi, M. Hoffman, S. Powell, Y. Yamada, H. Kleinman, and K. Malinda. 1999. Identification of endothelial cell binding sites on the laminin  $\gamma$ 1 chain. *Circ. Res.* **84**:688-694.

- Salcedo, R., H. Young, M. Ponce, J. Ward, H. Kleinman, J. Murphy, and J. Oppenheim. 2001. Eotaxin (CCL11) induces *in vivo* angiogenic responses by human CCR3<sup>+</sup> endothelial cells. *J. Immun.* **166**:7571-7578.
- Eisenstein, M. 2006. Thinking outside the dish. *Nature Methods* **3**:1035-1043.
- Benton, G., J. George, H.K. Kleinman, and I.P. Arnaoutova. 2009. Advancing Science and Technology Via 3D Culture on Basement Membrane Matrix. *J. Cell. Physiol.* **221**:18-25.
- Arnaoutova, I., J. George, H.K. Kleinman, and G. Benton. 2009. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. *Angiogenesis* doi:10.1007/s10456-009-9146-4
- U.S. Patent 4,829,000
- U.S. Patent 5,158,874

This product is made and marketed under patent license from the United States Public Health Service. Ref. U.S. Patent 4,829,000 issued May 9, 1989 and U.S. Patent 5,158,874 issued October 27, 1992, all entitled Reconstituted Membrane Complex with Biological Activity.



**BME**  
**PathClear<sup>®</sup>**

Cat#: 3432-005-02  
Storage: ≤ -20 °C  
(Manual Defrost)  
1-800-873-8443

#### Lot Specific Data:

Protein Concentration:  
Endotoxin (LAL):  
Size: